BIORA THERAPEUTICS, INC.: Nasdaq/NYSE listing notice — Biora Therapeutics cures Nasdaq listing deficiency; stock to remain on Global Market

BIORA THERAPEUTICS, INC.

Nasdaq confirmed Biora cured noncompliance with $50M total assets and $50M total revenue continued listing requirement.
The matter is closed; common stock remains listed on The Nasdaq Global Market.
Letter received June 8, 2023; no further action needed from Company.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

BIORA THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding other.

Exchange: nasdaq
Notice: compliance regained

Exact text from the filing

June 8, 2023, Biora Therapeutics, Inc. (the “ Company ”) received a letter (the “ Compliance Letter ”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company’s previously announced noncompliance with the $50 million in total assets and $50 million in total revenue requirement for continued listing on The Nasdaq Global Market has been cured. Accordingly, the Compliance Letter provided that the matter has been closed with Nasdaq. The Company’s common stock will continue to be listed and traded on The Nasdaq Global Market. SIGNATUR

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001193125-23-163496

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.